LIVZON PHARMAC. GRP H YC1
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, il… Read more
LIVZON PHARMAC. GRP H YC1 (LP6) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, LIVZON PHARMAC. GRP H YC1 (LP6) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
LIVZON PHARMAC. GRP H YC1 - Net Assets Trend (None–None)
This chart illustrates how LIVZON PHARMAC. GRP H YC1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LIVZON PHARMAC. GRP H YC1 (None–None)
The table below shows the annual net assets of LIVZON PHARMAC. GRP H YC1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to LIVZON PHARMAC. GRP H YC1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
LIVZON PHARMAC. GRP H YC1 Competitors by Market Cap
The table below lists competitors of LIVZON PHARMAC. GRP H YC1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Ramco Cements Limited
NSE:RAMCOCEM
|
$1.42 Billion |
|
AtriCure Inc
NASDAQ:ATRC
|
$1.42 Billion |
|
Aroundtown SA
PINK:AANNF
|
$1.42 Billion |
|
Glarun Technology Co Ltd
SHG:600562
|
$1.42 Billion |
|
American Superconductor Corporation
NASDAQ:AMSC
|
$1.42 Billion |
|
Fujian Huoju Electronic
SHG:603678
|
$1.42 Billion |
|
Nektar Therapeutics
NASDAQ:NKTR
|
$1.42 Billion |
|
Vericel Corporation
F:ATQP
|
$1.42 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LIVZON PHARMAC. GRP H YC1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares LIVZON PHARMAC. GRP H YC1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently LIVZON PHARMAC. GRP H YC1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares LIVZON PHARMAC. GRP H YC1's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LIVZON PHARMAC. GRP H YC1 (LP6) | €- | N/A | N/A | $1.42 Billion |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |